PsiOxus, Parker Institute for Cancer Immunotherapy plan to partner on tumor-specific immuno-gene therapy

The MoU confirms PICI and PsiOxus’s interest in working together to develop and test novel "armed" oncolytic viral constructs utilizing PsiOxus’ proprietary T-SIGn platform and manufacturing capabilities.

Under the anticipated collaboration, the Parker Institute would convene key scientific and clinical thought leaders from its network to prioritize novel virus designs, including genetic payloads intended to prime or otherwise beneficially modify the tumor microenvironment for immune infiltration.

PsiOxus would then manufacture the candidate viruses and make them available for research use by Parker Institute researchers, including for Parker Institute supported clinical trials and other types of studies, as well as in combination with other clinical agents.

The commercial terms of this agreement remain subject to further discussion and agreement.

Commenting on the PICI launch, Dr. Beadle, CEO of PsiOxus, said: "We are proud to be a part of this very exciting period of advancement in immunotherapy for cancer patients. It is our hope that the combination of our T-SIGn platform with the world class expertise and resources of the Parker Institute will result in fundamental steps forward in the understanding of cancer immunology as well as the development of future generations of cancer immunotherapies that will provide lasting benefits to patients for many years to come."